The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Randomized Controlled Trial
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials. ⋯ These two phase 3 studies show the efficacy of canakinumab in systemic JIA with active systemic features. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT00889863 and NCT00886769.).